Atypical chronic myeloid leukemia following organ transplants

V. Fontana, P. Dudkiewicz, L. L. Horstman, A. G. Tzakis, Yeon Ahn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Secondary malignancy frequently develops among recipients of organ transplants, most commonly malignancies of the lymphoid system and skin. However, chronic myeloid leukemia (CML) is rare following transplant, with only a handful of cases reported, all of whom had kidney transplant and received azathioprine for immunosuppression. We report three cases of post-transplant CML seen at a single institution within a two-yr period. Two had received liver and one a kidney transplant. None were on azathioprine but all had tacrolimus. CML is a rare hematological malignancy, usually presenting with high white counts and splenomegaly. In all three of our subjects, presentation of CML post-transplant was so atypical that their diagnosis could easily be missed. All had rapid and excellent response to imatinib, and underwent clinical remission. This is the first report of CML developing in the course of tacrolimus therapy among liver transplant recipients. Presentations of CML were highly atypical and easy to miss in early stage. Awareness of atypical CML developing post-transplant is important since early and timely therapeutic intervention with imatinib is critical for improving quality of life and overall prognosis.

Original languageEnglish
Pages (from-to)258-261
Number of pages4
JournalClinical Transplantation
Volume22
Issue number2
DOIs
StatePublished - Mar 1 2008

Fingerprint

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplants
Azathioprine
Tacrolimus
Kidney
Liver
Splenomegaly
Hematologic Neoplasms
Immunosuppression
Neoplasms
Quality of Life
Skin

Keywords

  • Chronic myeloid leukemia
  • Immunosuppression
  • Malignancies
  • Organ transplant
  • Philadelphia chromosome
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Fontana, V., Dudkiewicz, P., Horstman, L. L., Tzakis, A. G., & Ahn, Y. (2008). Atypical chronic myeloid leukemia following organ transplants. Clinical Transplantation, 22(2), 258-261. https://doi.org/10.1111/j.1399-0012.2007.00775.x

Atypical chronic myeloid leukemia following organ transplants. / Fontana, V.; Dudkiewicz, P.; Horstman, L. L.; Tzakis, A. G.; Ahn, Yeon.

In: Clinical Transplantation, Vol. 22, No. 2, 01.03.2008, p. 258-261.

Research output: Contribution to journalArticle

Fontana, V, Dudkiewicz, P, Horstman, LL, Tzakis, AG & Ahn, Y 2008, 'Atypical chronic myeloid leukemia following organ transplants', Clinical Transplantation, vol. 22, no. 2, pp. 258-261. https://doi.org/10.1111/j.1399-0012.2007.00775.x
Fontana, V. ; Dudkiewicz, P. ; Horstman, L. L. ; Tzakis, A. G. ; Ahn, Yeon. / Atypical chronic myeloid leukemia following organ transplants. In: Clinical Transplantation. 2008 ; Vol. 22, No. 2. pp. 258-261.
@article{64dcc3741a9a4960a45373cdd7a38444,
title = "Atypical chronic myeloid leukemia following organ transplants",
abstract = "Secondary malignancy frequently develops among recipients of organ transplants, most commonly malignancies of the lymphoid system and skin. However, chronic myeloid leukemia (CML) is rare following transplant, with only a handful of cases reported, all of whom had kidney transplant and received azathioprine for immunosuppression. We report three cases of post-transplant CML seen at a single institution within a two-yr period. Two had received liver and one a kidney transplant. None were on azathioprine but all had tacrolimus. CML is a rare hematological malignancy, usually presenting with high white counts and splenomegaly. In all three of our subjects, presentation of CML post-transplant was so atypical that their diagnosis could easily be missed. All had rapid and excellent response to imatinib, and underwent clinical remission. This is the first report of CML developing in the course of tacrolimus therapy among liver transplant recipients. Presentations of CML were highly atypical and easy to miss in early stage. Awareness of atypical CML developing post-transplant is important since early and timely therapeutic intervention with imatinib is critical for improving quality of life and overall prognosis.",
keywords = "Chronic myeloid leukemia, Immunosuppression, Malignancies, Organ transplant, Philadelphia chromosome, Tacrolimus",
author = "V. Fontana and P. Dudkiewicz and Horstman, {L. L.} and Tzakis, {A. G.} and Yeon Ahn",
year = "2008",
month = "3",
day = "1",
doi = "10.1111/j.1399-0012.2007.00775.x",
language = "English",
volume = "22",
pages = "258--261",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Atypical chronic myeloid leukemia following organ transplants

AU - Fontana, V.

AU - Dudkiewicz, P.

AU - Horstman, L. L.

AU - Tzakis, A. G.

AU - Ahn, Yeon

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Secondary malignancy frequently develops among recipients of organ transplants, most commonly malignancies of the lymphoid system and skin. However, chronic myeloid leukemia (CML) is rare following transplant, with only a handful of cases reported, all of whom had kidney transplant and received azathioprine for immunosuppression. We report three cases of post-transplant CML seen at a single institution within a two-yr period. Two had received liver and one a kidney transplant. None were on azathioprine but all had tacrolimus. CML is a rare hematological malignancy, usually presenting with high white counts and splenomegaly. In all three of our subjects, presentation of CML post-transplant was so atypical that their diagnosis could easily be missed. All had rapid and excellent response to imatinib, and underwent clinical remission. This is the first report of CML developing in the course of tacrolimus therapy among liver transplant recipients. Presentations of CML were highly atypical and easy to miss in early stage. Awareness of atypical CML developing post-transplant is important since early and timely therapeutic intervention with imatinib is critical for improving quality of life and overall prognosis.

AB - Secondary malignancy frequently develops among recipients of organ transplants, most commonly malignancies of the lymphoid system and skin. However, chronic myeloid leukemia (CML) is rare following transplant, with only a handful of cases reported, all of whom had kidney transplant and received azathioprine for immunosuppression. We report three cases of post-transplant CML seen at a single institution within a two-yr period. Two had received liver and one a kidney transplant. None were on azathioprine but all had tacrolimus. CML is a rare hematological malignancy, usually presenting with high white counts and splenomegaly. In all three of our subjects, presentation of CML post-transplant was so atypical that their diagnosis could easily be missed. All had rapid and excellent response to imatinib, and underwent clinical remission. This is the first report of CML developing in the course of tacrolimus therapy among liver transplant recipients. Presentations of CML were highly atypical and easy to miss in early stage. Awareness of atypical CML developing post-transplant is important since early and timely therapeutic intervention with imatinib is critical for improving quality of life and overall prognosis.

KW - Chronic myeloid leukemia

KW - Immunosuppression

KW - Malignancies

KW - Organ transplant

KW - Philadelphia chromosome

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=41049108270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41049108270&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2007.00775.x

DO - 10.1111/j.1399-0012.2007.00775.x

M3 - Article

VL - 22

SP - 258

EP - 261

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -